Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com
The researchers say that the pattern where papers and patents seem increasingly less likely to result in disruptive innovation was found to be universal throughout scientific and technological fields. Additionally, the decline was observed in multiple citation and text-based metrics.
Attempting to understand why it is occurring, and what it means, the authors say they link the decline to a reduced reliance on the use of previous knowledge.
“We find that the observed declines are unlikely to be driven by changes in the quality of published science, citation practices or field-specific factors,” the authors note. “Overall, our results suggest that slowing rates of disruption may reflect a fundamental shift in the nature of science and technology.” The team’s findings appeared in a paper titled “Papers and patents are becoming less disruptive over time,” which appeared in the journal Nature.
CAUSE FOR CONCERN?
Considering that the “quality of published science” is cited as a factor in this equation, should we be concerned about the current efforts in innovation, and what that could mean for the future?
Northwestern University computational scientist Dashun Wang says that although he is convinced by the data presented in the paper, it may not necessarily mean that scientific and technological growth have grown entirely stagnant. He points to the first observation of gravitational waves in recent years, a revolutionary development that was also the result of incremental scientific advancement.
Artist’s concept of gravitational waves surrounding two black holes (Credit: Credit: Henze/NASA).
Although disruptive advancements have long been a driving force in scientific and technological growth, the observed trend by Funk, Park, and Leahey could simply mean that as more and more knowledge is accumulated, the way that science advances is changing, which may not be an entirely bad thing.
Aviva Lev-Ari, PhD, RN Aviva Lev-Ari, PhD, RN• You• YouFounder 1.0 LPBI and 2.0 LPBI at Leaders in Pharmaceutical Business Intelligence GroupFounder 1.0 LPBI and 2.0 LPBI at Leaders in Pharmaceutical Business Intelligence Group
12h • 12 hours ago
Outstanding accomplishment by Mira Murati, another example of the contribution of WOMEN immigrants to Science and Technology in the US. #ChatGPT#openai @MIT
Wafik S. El-Deiry, MD, PhD, FACP, FRSMWafik S. El-Deiry, MD, PhD, FACP, FRSM(He/Him) • 1st(He/Him) • 1stAssociate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RIAssociate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI
19h • 19 hours ago
Mira Murati: The Albanian Woman Who Developed ChatGPT
Mira Murati: The Albanian Woman Who Developed ChatGPT – Global Woman Magazine
globalwomanmagazine.com • 3 min read
Reactions
Like
313 impressions
SciSpace
@scispace_
This ChatGPT-powered assistant is simplifying research papers for millions of scholars worldwide. Follow SciSpace to learn more. #ChatGPT#Research#AcademicChatter#AI
Following
16
42
197
308.3K
What ChatGPT And Generative AI Mean For Your Business?
Forrester just published a report on generative AI that tells its enterprise clients not to ignore or downplay its impact.Enterprises should start right now to experiment with generative AI, recommends Forrester, focusing on existing processes that can be enhanced by technologies “that leverage massive corpuses of data, including large language models, to generate new content (e.g., text, video, images, audio, code).”
It would be “a costly mistake,” says Forrester, to ignore the potential of generative AI to enable production of content at scale, to accelerate the speed and precision of data science practices and app development, to produce synthetic data for training AI and machine learning models, and to provide new defense opportunities for security professionals. In short, generative AI presents an opportunity to augment and even automate existing work processes in IT, marketing, customer service and other business functions.
Human Writer or AI? Scholars Build a Detection Tool
DetectGPT can determine with up to 95% accuracy whether a large language model wrote that essay or social media post.
Valuation-based on Page Downloads of the English Edition – Aviva’s New Excel file Book-of-Business
Updates for 2022 – Website stat
Article Views 2020, 2021, 2022
UPDATED to 1/1/2023 –>> February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Use AI to achieve digital transformation – Advances in Instrument Intelligence
From: Wiley <e-service@wiley.com> Reply-To: Wiley <e-service@wiley.com> Date: Tuesday, January 10, 2023 at 8:04 AM To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu> Subject: Use AI to achieve digital transformation
The laboratory workflow is changing rapidly to keep up with today’s fast-paced world. Thus, it is necessary that products and people also adapt, not only to increase productivity but also to eliminate anomalies or inconsistencies induced by human error and variations in processes.
Some of the main challenges in this process include:
Sophisticated quality control to restrain errors.
Advanced analytics to obtain meaningful information or reliable diagnostics.
Data reproducibility.
This eBook presents an overview of instrument intelligence solutions and shows how several lab sectors can be modified to have faster and error-free production. This can be especially achieved with digitalization and digital transformation.
The content of this eBook consists of:
A summary of Wiley’s book “Digital transformation of the lab”, discussing opportunities, needs, and challenges related to the role of artificial intelligence (AI) in transforming laboratories.
A summary of an article on the “industrial” revolution in biomedical research.
An infographic on Agilent’s intelligent Reflex workflow tool.
5:00PM – 5:30PM
Free Book Promotions
A Free Book Promotion allows you to attract new readers and widen your audience. You can offer your Kindle eBook for free for up to 5 days out of each 90-day KDP Select enrollment period. Free Book Promotions are for Kindle eBooks only and are available in all KDP marketplaces.
You can schedule a Free Book Promotion after your Kindle eBook is enrolled in KDP Select and available for sale on Amazon. To schedule a Free Book Promotion, follow the steps below:
From: WIRED’s Steven Levy <wired@newsletters.wired.com> Reply-To: <hello@wired.com> Date: Friday, December 9, 2022 at 9:55 AM To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu> Subject: [Correction] Elon Musk’s Twitter is making Meta look smart
Science Side
1PM – 3PM
Dr. Williams on:
Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software
Create an Author Page through Amazon Author Central so readers can get information about you and your work. You can join Amazon Author from here. Already have an Author Page? Make sure you claim all of your books, including this one. When you add your books, they become eligible for our monthly KDP Select All-Stars bonus program.
From: “Dr. Stephen J. Williams” <sjwilliamspa@comcast.net> Date: Sunday, November 13, 2022 at 1:08 PM To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> Subject: Elon Musk, Twitter, crypto and Twitter and online payment
Twitter has been toying with this idea of a payment system over Twitter but that was always US dollars
Elon always has been a big crypto backer
However there are three points
SEC and Treasury are moving fast for regulation given FTX collapse late last week
crypto as I have seen it is actually a defationing asset…. purchase power of crypto actually seems to decrease given fees
USD will have to back it as nothing backs the crypto … people will always trust USD over an electronic currency for at least next decades
just a few of my observations but they could make Twitter a crypto type wallet and do payment systems. It would be interesting to see then how worth followings or Twitter accounts would become or valued
Science Side
1PM – 3PM
Dr. Williams on:
Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation
Relations between VC investment and Unicorn status
Status is online
Ilya Strebulaev• 1stProfessor at Stanford Graduate School of Business | Venture Capital & Private Equity1d • 1 day ago
There is much talk about California losing its status as the startup land. My team and I looked into whether California has been producing fewer unicorns over the past 30 years. The answer is no, but we found other surprising facts.
Over the entire period, California, New York, and Massachusetts are the top 3 states by the “production” of US VC-backed unicorns in absolute numbers. 544, 110, and 74 unicorns respectively come from each state.
California holds a stable share over 30 years at about 50% of all companies that become unicorns each year.
New York has become increasingly important in recent years. From just 3% of the unicorns 20 years ago to 12% and the second place today. It is also the fastest growing US unicorn hub.
Massachusetts, in the third place, holds the 5%-8% range over time.
Israel is the top foreign nation in terms of absolute number of US-based unicorns with 29 companies from Israel calling the US home.
Based on the 2011-2020 decade, Israel alone would have been the fourth by the absolute number of US unicorns were it a US state, surpassed only by CA, NY, and MA. This is quite a fact! Israel is rivaling Massachusetts, as its share has grown from 0 to 5% in the last 20 years.
Stay tuned to explore more evidence behind the success and distribution of startup hubs.
We go ahead and upload to Amazon.com New Genre Text file with LINKS for Audio on WordPress.com
Issues with BeyondWords.com – Text-to-Audio conversion
From: “Rachel Handley from beyondwords.io” <support@beyondwords.io> Reply-To: “Rachel Handley from beyondwords.io” <support@beyondwords.io> Date: Monday, October 10, 2022 at 4:36 AM To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu> Cc: Hanoch Lev-Ari <levari@coe.neu.edu> Subject: Re: OUR BioMed e-Series in Audio Spanish and Audio English
Hi Aviva,
I recommend that you switch off automatic processing and create audio manually instead. This will allow you to create audio for each book subsection, which will provide a better listening experience and reduce the risk of errors.
You can create these smaller audios using our Text-to-Speech Editor and then manually embed the player into each section (you can customize the player text to say ‘Listen to this section’ or similar).
For your Spanish-language content, I recommend that you create a new project. Again, I would create the audio in the Text-to-Speech Editor and embed the player manually.
If you would like to proceed, you will need to switch to one of our new plans so that you can create a higher volume of audios.
Best,
Rachel
ISSUES with TTS
Series A, Volume 1 is audio enabled
We are exploring a manual method for text selection for conversion to audio vs automatic
10/4/2022:
We recommend creating your audio manually. This will allow you to break audio down into smaller sections and eliminate any unnecessary text, which should be more appealing to your audience. You can then embd these manually and/or gather them into a playlist if you like — please see section 1 here: https://beyondwords.io/knowledge-base/audio-content-playlist-ideas
4PM EST- 5PM EST
Status for Publishing 18+1 NEW e-Books on Amazon.com
GTO Presentation on Spanish content promotion methods and budgets
1PM EST – 1:30PM EST
Montero on capabilities for translation to additional languages
Meeting ended at 3PM
@@@@@
Agenda for September 13, 2022
11AM EST – 5:30PM EST
Zoom link will be sent on 9/12 at 5PM EST
Business Side
11AM EST – 11:15AM EST
Issues with BeyondWords.com
Text-to-Sound conversion for 19 Books in Audio Spanish
From: Rachel Handley from beyondwords.io <support@beyondwords.io> Sent: Friday, September 9, 2022 4:12 AM To:levari@coe.neu.edu Subject: RE: How do I generate audio for an existing page in my WordPress website?
Hi again,
Thank you for your patience with this issue. After investigating further it seems we are experiencing issues due to the high number of paragraphs in the content. We are trying to find a workaround and will let you know once we have an update.
If your team has time, I would recommend creating your audio manually. This will allow you to break audio down into smaller sections and eliminate any unnecessary text, which may be more appealing to your audience. You can then gather these into a playlist if you like — please see section 1 here: https://beyondwords.io/knowledge-base/audio-content-playlist-ideas
11:15AM EST – 12:15AM EST
Meetings with Business Broker, John R. on LPBI Exit
John R. will present 45 minutes followed by 15 minutes Q&A
12:15 – 12:30
Other forthcomingMeetings with Business Brokers
THU, Sept. 1, 2022, 1PM EST
Zoom with Aviva and John R.
FRI, Sept 2, 2022, 11AM EST
Zoom with Aviva and Matt M.
TUE Sept 6, 9AM EST – 10AM EST
Zoom with Aviva and Peter Q.
TUE Sept 6, Noon EST
Zoom with Aviva and Phil W. and David J.
WED Sept 14, 2PM EST
Zoom with Aviva and David H.
12:30AM EST – 12:45AM EST
Aviva on the need to create a 2022-2023 Elevator Pitch
LPBI Group’s venturesneed to bepositioning us as two ventures:
1.0 LPBI, 2012 – 2020 – a scientific publisher
2.0 LPBI Group, 2021 – 2025 – a software powerhouse with four missions (pipelines)
2022-2023 Elevator Pitch needs to incorporate the following achieved Milestones/Accomplishments to date
This Elevator Pitch for 1.0 LPBI, 2012 – 2020 does not include all the PROGRESS accomplished at 2.0 LPBI Group, 2021 – 2025:
Status of 2.0 LPBI Group’s four pipelines is as follows:
Mission #1: NLP (completed):
NEW GENRE NLP
Genomics Volume Three and
NEW GENRE Cancer Volume One
both include the Text analysis of the respective original volume processed by NLP algorithms: What are the results and the Domain Knowledge Expert interpretation
2.0 LPBI Group’s Mission #1 (Text analysis with AI)
Series B: Genomics
New volume
NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP). It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research
PART A.1: The eTOCs in Spanish in Audio format AND
PART A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format
PART B:
The graphical results of Medical Text Analysis with Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format
PART C:
The Editorials of the original e-Book in English in Audio format
Mission #2: Blockchain & NFT – work-in-progress
Erich is the Lead
Results of DB Schema Phase 1 will be presented on 10/11 Board meeting, results expected from inters on end of 9/2022
Please review
Blockchain Infrastructure we are developing for content monetization [2.0 LPBI Group’s Mission #2]
and colleagues describe how a rule-based algorithm for automatic multi-disease state classification from radiology text reports was used for automatic multi-organ classification from CT scans. (1/3)
Duke Center for AI in Radiology (DAIR)
@duke_dair
·
The automatically extracted labels were 91-99% accurate compared to ground truth validation. More details can be found in the attached paper. https://arxiv.org/abs/2008.01158 (2/3)
arxiv.org
Classification of Multiple Diseases on Body CT Scans using Weakly…
Purpose: To design multi-disease classifiers for body CT scans for three different organ systems using automatically extracted labels from radiology text reports. Materials & Methods: This…
Series A: Six volumes are ready for Text to Audio conversion
Series B: Three Volumes 1&2 are ready for Text to Audio conversion 3rd Volume is Results of Text Analysis with NLP – pending Dr. Williams upload of plots and Interpretation
Series C: Two volumes are ready for Text to Audio conversion, volume 1 includes NLP results and Interpretation – pending upload of plots
Series D: One out of Four volumes are ready for Text to Audio conversion
Series E: PENDING
Results of Medical Text Analysis with Natural Language Processing (NLP) presented in LPBI Group’s NEW GENRE Edition: NLP on Genomics content, standalone volume in Series B and NLP on Cancer content as Part B New Genre Volume 1 in Series C
The newly sequenced regions include previously inaccessible sections such as the centromeres, the tightly wound central portions of chromosomes that keep the long double strands of DNA organized as the strands unwind, bit by bit, to copy themselves and separate into two cells as a single cell divides. These regions are critical for normal human development and also play a role in brain growth and neurodegenerative diseases. “It’s been one of the great mysteries of biology that all eukaryotes—all plants, animals, people, trees, flowers and higher organisms—have centromeres. It’s a really fundamental part of how DNA replicates and how chromosomes organize and how cells divide. But it’s been a great paradox, because while its function has been around for billions of years, it was almost impossible to study because we didn’t have a centromere sequence to look at,” says Schatz. “Now we finally do.”
Biotech startup with AlphaGo-type AI approach snags $30M
The CEO of Anagenex believes that the company’s AI engine trained on billions of data points and iterative testing will blow other AI drug discovery startups out of the water.
Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
Dan Boneh, professor of computer science. Professor Boneh heads the applied cryptography group and co-directs the computer security lab. His research focuses on applications of cryptography to computer security. Professor Boneh’s work includes cryptosystems with novel properties, cryptography for blockchains, and cryptanalysis. He has authored over 150 publications in the field and has received the 2014 ACM prize, the 2013 Godel prize, and the RSA award in mathematics. In 2016, Professor Boneh was elected to the National Academy of Engineering.
This talk was recorded at Stanford Reunion 2021.
VIdeos by Prof. Dan Boneh, Stanford University, CS Department
I need to understand better the algorithm that related the these 3 factors:
A. the price of my NFT
B. the price to MINT this NFT
C. the traffic at the moment the MINTING process is complete
D. Average traffic daily during 90 days of my Experiment design for 14 articles
E. Bidding: Do I have to accept the bid during first 5 days
F. What is my recourse – can I delist an NFT??
G. Can I declare Limited Edition: Article x will sell 100 copies and Article Y 300 copies??
1PM EST – 2PM EST – Aviva – INTERNAL to LPBI Group
#1: Scoring system for Equity sharing calculation based on 1.0 LPBI Group’s IP Asset class I: Journal articles
Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
#2: LinkedIn 1st degree connections by Biotech Company Name and by Connections positions
Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus
Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and All Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON
Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author and multiple authors)(b) Total Articles Views and (c) Author’s Proportion of own articles views in the Top 14 Journal articles by Views
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus
Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025 and Data Scientist, Research Assistant III: Tianzuo George Li
rmdsNFT.commarketplace DEMO for LPBI Group by Samantha and Vincent
2:30PM EST – 3:15PM EST
Prof. Feldman, Presenter
&
Prof. Williams, Discussant
Why Biology Is Not Destiny
New York Review of Books, 21 April 2022: 43-46.
M.W. Feldman and Jessica Riskin
The Genetic Lottery: Why DNA Matters for Social Equality
by Kathryn Paige Harden.
Princeton University Press,
300 pp., $29.95
You must know the parable about the frog that sits in a pot of water being gradually heated, allowing itself to be boiled alive: because the change happens gradually, it never realizes it should leap out. Reading Kathryn Paige Harden’s book The Genetic Lottery: Why DNA Matters for Social Equality is a similar experience, as the author ingenuously points out. “Like a frog being slowly boiled alive,” she observes, readers follow her argument “from an uncontroversial premise to a highly controversial one.” Harden’s “uncontroversial premise” in this case is that siblings raised in the same family share a childhood environment and 50 percent of their DNA randomly assigned at conception, and are therefore like subjects in a controlled study of genetic differences. Ask anyone with a sibling whether their own childhood environment was the same as their sibling’s and you’ll quickly disprove Harden’s claim that her premise is uncontroversial. But putting that objection aside and sitting patiently as Harden increases the heat, we’ll arrive at her “highly controversial” assertion that “if siblings who differ genetically also have corresponding differences in their health or well-being or education, this is evidence that genes are causing these social inequalities.”
Harden is a dedicated frog boiler. She introduces many comfortably room-temperature premises: measurement is essential to science; people differ genetically; genes cause conditions such as deafness; a recipe for lemon chicken produces variable results but never leads to chocolate-chip cookies. Lulled to complacency by such anodyne and often homey observations, we soon find ourselves in a rolling boil of controversial claims: genes make you more or less intelligent, wealthier or poorer; every kind of inequality has a genetic basis.
SOURCE
M.W. Feldman and Jessica Riskin. “Why Biology is Not Destiny.” New York Review of Books, 21 April 2022: 43-46.
3:15PM EST – 4:00 PM EST
DISCUSSION on LPBI Group’ Strategy Options related to rmdsNFT.commarketplace DEMO for LPBI Group by Samantha and Vincent
Q&A
I need to understand better the algorithm that related the these 3 factors:
A. the price of my NFT
B. the price to MINT this NFT
C. the traffic at the moment the MINTING process is complete
D. Average traffic daily during 90 days of my Experiment design for 14 articles
E. Bidding: Do I have to accept the bid during first 5 days
F. What is my recourse – can I delist an NFT??
G. Can I declare Limited Edition: Article x will sell 100 copies and Article Y 300 copies??
Aviva needs an Account and Wallet with rmdsNFT.com for ALL her NFTs created Prior to 4/2012 – the Launch of PharmaceuticalIntelligence.com – deposits in the Wallet will be from Aviva’s own funds for covering Fees
Under 2, above: PROPOSAL #2: Aviva will present on 4/12 – 3 Volumes on a Combination Drug therapy in Cardiovascular – Each chapter in each Volume is an NFT. The content of each Volume needs to be decomposed into many NFTs
Under 2, above: PROPOSAL #3: Aviva will present on 4/12 – 3 Volumes on the 1st e-Mall for Analytics for Digital Marketplaces – this is the predecessor of the 2022 Blockchain IT architecture. The content of each needs to be decomposed into many NFTs
To MINT NFTs for PROPOSALS #1,2,3, above, Aviva and LPBI need HELP from rmdsNFT.com
LPBI’s Gallery of IMAGES: 2012 – 2022 – ~7,000 items Should be prioritized as PROPOSAL #4.
4:00PM EST – 5PM EST
Business Side
Group Discussion on Business Matters to be presented
OT-1.0
CS-2.0
@@@@@@@@@
AGENDA for March 15, 2022
Science Side
March 15, 2022 @ 11AM EST
11AM EST – Noon
LECTURE TITLE on 3/15/2022
Dr. Shraga Rottem, MD, DSc
Clinically Applicable Artificial Intelligence in Women’s Healthcare, Reproduction and Maternal-Fetal Medicine
Technion Prof. Emeritus Yoram Palti of the Faculty of Medicine will receive the 2022 Israel Prize in the Field of Entrepreneurship and Technological Innovation
Our ecosystem platform at GRMDS.org does have search feature.
Our NFT marketplace can support to mint and list your assets to be sold on our marketplace.
We can deploy a window or connect to your web site for your members’ easy access to our marketplace, and for your members’ easy minting, listing, selling IP NFTs.
See attached an introduction, and we can use our marketplace to support you and your communities.
Messages exchange on LinkedIn on 2/11/2022
Business Side @ 1PM EST
ERICH: STATE of Technology – 20 minutes
AVIVA: STATE of STRATEGY – 40 minutes
On the blockchain we intend to SELL each Plot: Hyper-graphs and Tree Diagrams
On the blockchain we intend to SELL each Interpretation like the two in Science Side today
In a B2C Scenario: A knowledge worker type a query
Option 1: one article with most views on the topic is shown on the screen
Option 2: 12 top articles are fetched from the Journal archive ranked by views
Option 3: computer advise [Recommendation Engine] the knowledge worker: x articles in this 12 were published in the following books
Option 4: do you wish to see the NLP results of these articles in the context of the chapter they are included in the books?
Option 5: if yes, then Hyper-graph and Tree diagram stored in the DB is retrieved and appears on the screen
Option 6: do you wish to read the interpretation of the Domain Knowledge Expert for these graphs?
Option 7: if yes, Interpretation Box appears on the screen
Option 8: Knowledge worker wish to download to his computer Options 2,3,4,5,6,7,
Option 9: Price for Option 2 = $20, Option 3 = #40$ Option 4,5,6,7 =$35 each
Option 10: Form with itemized contents for a total of $200
Option 11: Credit card online payment
Option 12: all paid for items are downloaded to the B2C Knowledge worker CART
THAT IS A TRANSACTION OF CONTENT MONETIZATION recorded on the blockchain
Business Side @ 2PM EST
Business Model in MEDIA acquisitions
A. Padre Media – Could they be a potential M&A target
B. Deloitte is expanding its Converge portfolio to serve retail and financial services as well as health
The folks at Deloitte, who have the good sense to sponsor this newsletter, have some news of their own this morning. They are announcing a planned $750 million investment to build out their ConvergeHEALTH business by adding ConvergeCONSUMER and ConvergePROSPERITY to serve the retail and financial services sectors.
INOVA is a software company for Pharma with acquisition of LaBiotech they added the Biotech sector – the Partnering involved a Global DB of clients in these industries.
CONTENT PROMOTION is a must for LPBI Group’s Content Monetization
We are building the Blockchain IT platform to Index all our IP Assets for Monetization
INOVA via One to One Partnering have a computerized system in Pharma via LaBiotech acquisition also Biotech of Customers, CRM
Areas Aviva sees LPBI IP assets to be of relevance:
1. OUR CONTENT (Journal articles and Books) is king for an information push model to theirs computerized Global Pharma and Biotech (Europe focus) clients.
2. LPBI Group’s Conference e-Proceedings and Tweet Collections – is relevant for INOVA’s Conference involvement via One-on-One Partnering. Inova is also the company behind the One-on-One Partnering system used by the BIO International Convention, the largest biotech gathering in the world!
3. Spanish books for All Customers in Spanish speaking Countries: Spain, Latin America and South east Asia
4. Blockchain for auctioning of NFT:
4.1 LPBI’s Curation [80% of 6,112 articles]
4.2 Discovery Searches across several LPBI’s IP assets
4.3 Therapeutics molecules designed with synthetic biology software PRossettaC for PROTACs on Galectins – 2.0 LPBI Group’s Mission #4
4.4 Molecules developed by 3rd parties
5. NLP on Genomics and Cancer – two books are NLP ready, other Books are wor- in-progress, LPBI Group’s launched in 2021
New Genre e-Series
[Demo Two Books by Aviva]
Science Side @ 3PM EST
Content Development for 2.0 LPBI Group’s
New Genre e-Series
Dr. Williams Interpretation of Hypergraph Plot for Cancer Volume 1, Chapter 3
The included hypergraph is a visualization of chapter 3 of Cancer Volume 1, represented by the extraction of 17 key concepts from the text of this chapter. This chapter focuses on the genetic complexity of cancer and how this genetic complexity affects tumor growth and metastases. Special emphasis is given to the complex structure of DNA in the chromatin as well as the dynamic flux of mobile elements and noncoding intronic sequences important in controlling gene and protooncogene expression. Some examples of this complexity is the heterogeneity of tumors, the ability of viruses to cause liver cancer, and the importance of variants in etiology and predisposition of cancers of the breast and gastric system. An interesting insight, potentially not visible unless given the visualization analysis, is the association between genomics, heritable mutations and with growth control of adenomas, especially for the colorectal system. Also inferred is that genomic effects may be more prominent in early tumorigenesis than in late stage although this would differ from the previous analysis of chapter 2. An explanation could be potential epigenetic changes are more important in late stage, as gleamed from this hypergraph. In addition, cellular processes may be governed by genomic, intronic (junk) DNA than previously thought. Cancer control may be associated with deleterious passenger mutations and associated with variant alleles and reflected in cancer heterogeneity. However it seems there is no connecting edge with the pathogenesis of cancer and those passenger mutations as may depend more on the driver mutations.
In summary, an interpretation of this hypergraph could be as follows:
Cancer is a complex genetic and epigenetic disease affecting multiple cellular processes. Tumor heterogeneity creates a complex pattern with multiple variants affecting outcomes, especially in solid tumors.
Dr. Williams Interpretation of Tree Diagram Plot for Cancer Volume 1, Chapter 3
Chapter 3 discusses the genetic basis of cancer and, as such, contains articles of a more technical nature. Discussions of structure of DNA, mobile and transposable elements in DNA, noncoding DNA, tumor heterogeneity, and various genetic drivers of specific cancers are discussed. The tree diagram projects the basis of these articles as genetic variants is closely associated with risk of cancer and structural elements of the DNA lattice, even considered a framework of DNA and thought once to be static, is associated with an active process of opening and relaxing, leading to an important concept when considering the importance of DNA as an active changing structure to the cancer development process.
The term adenoma is correctly classified by the algorithm as a benign tumor but very interesting its close proximity to cancer risk and variants, terms not canonically associated with adenomas except in the case of colorectal cancer, also discussed, where there are definitely a progression from adenomas to carcinomas with underlying genetic variant risk factors. Calcium is correctly identified as a metal and effects of its biodistribution is discussed in this chapter. Also interesting to note is that “variant” is associated with “type” and “quantity”, two areas of active investigation as massive genomic studies are underway to determine and quantify risk variants in multiple populations, and the effects of variants to the risk of environmentally induced cancer development. The field of genomic epidemiology is a rapidly expanding field yet hampered by the inability to relate risk variants to causality. Perhaps a deeper analysis of the literature with enhanced ontological terms may provide some clues to help in these investigations. Issues of tumor heterogeneity, one article in the chapter, has ontologies related to stem cells {“renewal”}, type of variants, and probability of variants to risk of developing advanced and resistant tumors.
Topics for DECISION @4PM EST
Unicorn Behavior in the MarketPlace: Research by Prof. Ilya Strebulaev at Stanford University GSB
Steve Jobs by Walter Isaacson 21 min reading time audio version available Get the key ideas on Blinkist Buy on Amazon Just like Musk, Steve Jobs forged his own path in the tech industry. This book chronicles the audacious, adventurous life of the innovative entrepreneur and eccentric founder of Apple. Drawing from Jobs’s earliest experiences with spirituality and LSD to his pinnacle as a worldwide tech icon, Steve Jobs describes the man’s successful ventures as well as the battles he fought along the way. Get the key ideas with Blinkist in just 19 minutes.
APPENDIX for Business Side
BACKGROUND
INOVA – A cloud-based solution aimed at helping life science companies locate and manage their biopharma opportunities more efficiently
Inova Acquired Labiotech
About Inova
Inova is a cloud-based solution aimed at helping life science companies locate and manage their biopharma opportunities more efficiently. It offers a platform for partnering events, secure licensing and collaboration opportunities, and successful deal making and alliance management. Inova has over 125 employees and is headquartered in Lyon, France, with offices in New York, Denver, and Tokyo. Further information is available at inova.io. Follow Inova on LinkedIn and Twitter.
Inova was founded in 2010 by Gilles Toulemonde, David Carteret and Fritz Eisenhart by merging Inova and Vertical*i. The merger combined Vertical*i’s business development and alliance management expertise with Inova’s experience in strategic innovation software. The newly merged company turned its focus to creating a software that would help life sciences companies find external innovations. Since then, we’ve worked exclusively in the life sciences, learning the pains and challenges of this industry inside and out. We’re constantly developing new partnerships and new features to help biopharma companies work together better. For example, we have a strategic partnership with the Biotechnology Innovation Organization, organizer of the largest biopharma partnering event of the year. Thanks to this partnership, our CRM is prepopulated with company and contact information from BIO partnering meetings. The two systems are synchronized in real-time, providing our users with always up to date information and helping them find the right partners. https://inova.io/about/
About Labiotech
Labiotech is the publishing company of www.labiotech.eu, the leading news website for the biotech industry in Europe. Labiotech has 6 employees and is headquarter in Berlin, Germany.
We’ve got some amazing news we’re dying to tell you about, and now we can finally let the cat out of the bag:
Inova, the leading biopharma partnering platform has acquired Labiotech!
Ever heard of Inova? Inova is a cloud-based solution helping life science companies locate and manage their partnering opportunities more efficiently. The company already supports more than 150 global clients, including many of the world’s largest pharmaceutical companies, and is at the forefront of digital transformation in biopharma collaborations.
Inova’s flagship product, ‘Inova Partnering Platform’, is a collaborative tool used to manage all partnerships related to outsourced innovation to laboratories and biotechs, enabling customers to manage their biopharma alliances in one tool. Inova is also the company behind the One-on-One Partnering system used by the BIO International Convention, the largest biotech gathering in the world!
So why would a software company buy a media company?
Through this merger, Inova and Labiotech will be working together to offer the industry a unique space to connect with key players from both sides, stay informed on relevant updates, and manage all their partnering processes in one place.
But let’s get to the important stuff: what does this mean for you, our dear readers?
Simply that: more of the stuff you love!
Labiotech.eu will stay editorially independent and focused on high-quality journalism. Inova’s support will also bring us new resources to create even more content that you love! As always, we’ll keep most of it free to access and offer additional content to our members.
We’ll have more news on our future plans in the coming months. In the meantime, you can read the official press release here.
I also wish to thank our team, investors, partners, clients, and of course, our readers, for their support during the last 7 years. We would not be here today without all of you! It’s been an amazing journey and I’m thrilled to write the next chapter of Labiotech with our great team and our new partner Inova.
Spanish speaking countries – Market penetration for LPBI Group’s New Genre Scientific Books – Spanish eTOCs – 18 books in Medicine
Founder’s2022 Message
2022 Organizational Priorities
All Missions are pursued in parallel
Transfer of Ownership – URGENCY for Accomplishment. THIS IS PRIORITY #1: Involvement of multiple parties in the prospecting process: GPS, LDLC, XA, AB, GG
Combine Mission #1 (NLP) with Mission #3 (Spanish eTOCs) in publishing LPBI Group’s NEW GENRE e-SERIES. THIS IS PRIORITY #2: URGENCY for Delivery
NEW GENRE e-SERIES VERSION 1: PART A: Spanish eTOCs Audio, Bi-lingual eTOCs Text, PART B: NLP Results & NLP Expert Interpretation, PART C: Editorials English Audio
VERSION 1, Series B & C, Phase 1: Cancer Volume 1 and Genomics Volume 2; Phase 2: Genomics Volume 1 and Cancer Volume 2
NEW GENRE e-SERIES VERSION 2:
VERSION 2, Phase 1: Series A, six volumes – for each volume and for all six volumes in the series: PART A & PART C, above
VERSION 2, Phase 2: Series D, four volumes – for each volume and for all four volumes in the series: PART A & PART C, above
VERSION 2, Phase 3: Series E, four volumes – for each volume and for all four volumes in the series: PART A & PART C, above
3. Mission #2: Blockchain IT Platform for Content Monetization and Auctions of NFT: Molecules and Curations
Erich will present STATE OF AFFAIRS – 5 minutes
Fluree’s Environment for Knowledge Graph based Schema design and implementation for LPBI Group’s Journal’s Ontology
4. Mission #4: Synthetic Biology in Galectins Drug Discovery
Dr. Williamswill present STATE OF AFFAIRS – 5 minutes
PRossetaC and other platforms for AlphaFold and AI
Goal Attainment Scaling Record: 2021 – A Year in Review
We build a simplified package of 2 or 3 pages max that includes:
A teaser (see attached example)
Estimated income statement/financial forecasts (monetization, memberships, readership, subscription, a la carte, pay-per-article or pay-per-page/chart…)
Estimated value of assets. (with valuation methodology)
We build a simplified package of 2 or 3 pages max that includes:
· A teaser (see attached example)
· Estimated income statement/financial forecasts (monetization, memberships, readership, subscription, a la carte, pay-per-article or pay-per-page/chart…)
· Estimated value of assets. (with valuation methodology)
Bob Anderson
· Valuation of the IP
· Valuation of Composition of Matter
· SaaS and BaaS Models for 2.0 LPBI Group
Asked about referral to his contact Paulo
Erich on Mission #2: Blockchain with Fluree – Schema Design UPDATE
Erich will present update for his work with LMU CS MS Student on conversion of WordPress SQL DB into Fluree’s Knowledge Graph DB allowing for Blockchain deployment of 2.0 LPBI Portfolio of IP Asset Classes I to XIII [1.0 LPBI and 2.0 LPBI]
Aviva and Dr. Williams on Portfolio of IT Valuation
· Portfolio Valuation: Applicability of Non Fungible Tokens by IP Asset Class
NLP – Cancer, Volume 1, Chapters 7-12 – Overview of Keywords Extraction and Results of NLP – Satwik; Chapter 1: Danielle, Chapter 2: Dr. Pati and Chapters 3-6 – Satwik
NLP – Completion of Genomics, Volume 2 – Madison
· Aviva on Mission #3:
How LPBI Group plans to use the Spanish Translation of its BioMed e-Series: Cover page of 18 e-Books and electronic Table of Contents of these e-Books?
In November 2021 – I will start to convert the Spanish eTOCs to Sound files and will start to publish
LPBI Group’s
Medical eBooks New Genre Edition !!!!
· Spanish in Audio format,
· Bi-Lingual Text,
· NLP, Results and Domain Knowledge Expert Interpretations, and
· English Editorials in Audio format
Application of LPBI Group’s New Genre Edition of Medical Books:
Each Series: A, B, C, D, E – ONE Volume per Series – 5 volumes in Total
· Series A: Six volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
· Series B: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
· Series C: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
· Series D: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
· Series E: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
Each Volume: in each Series – 18 volumes in Total
· Part A: Bi-Lingual eTOCs,
· Part B: NLP, Results and Domain Knowledge Expert Interpretations
· Part C: Editorials English Audio
SEE YOU ALL ON December 14, 2021 AT 11AM EST
@@@@@@@@
October 12, 2021
LPBI Group’s Global Zoom Monthly Meeting,
10/12/2021, 11AM EST – 3PM EST
11AM – 12PM
Erich and Asala present
Progress report on Blockchain for LPBI’s SQL DATA SCHEMA
Input for Fluree Knowledge Graph Database Design,
Powering a Blockchain IT for Content Monetization for 2.0 LPBI
12PM – 1PM
Dr. Williams presents
Wolfram Platform: What can LPBI do to get access for MULTIPLE computers beyond 2 seats, currently held by Madison and by Yash – WHAT can we do with Wolfram to enable access to all INTERNS?
What is the state of development for the decision on the Software to be selected for Synthetic Biology for our Interns
HOW the work by David MacMillan on bio catalysts can be harnessed for our Synthetic Biology for Drug Discovery effort
Attempts to get External Presenters involved with Transfer of Ownership
Ongoing Strategy pursuits: Recap the four missions briefly as LPBI’s exposition of the pipelines for 2021 -2025:
Mission #1: NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences
Mission #2: Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.
Mission #3: BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E
UPDATED on 8/20/2021 by Dr. Williams – Presentation by Dr. Williams
Accomplishments for 3Q 2021 – Presentation by Aviva
IT & Data Science Internship – LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
Sign up agreement with SpeechKit – Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contract and was paid by a Loan Aviva made to LPBI. On 9/1/2021 wired the funds to cover the Invoice.
Instructions by Madison for all INTERNS on Deep Learning NLP using Yash’s code – is almost ready
Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
PowerPoint SLIDE DECK for 2.0 LPBI is Ready – Text by Aviva PPT by Srini and Abhisar
Completion of Internship Definition and Certificate Design on 9/2/2021 – Joint Work with Robin and Beth – SEE ATTACHMENTS
LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for
(a) Medical Text Analysis and
(b) Synthetic Biology Software for Drug Discovery
@@@@@@@
AGENDA for AUGUST 10, 2021, 11AM EST to 4PM EST
Global Monthly ZOOM Meeting
Strategies about and for
LPBI USA & LPBI India
PLEASE PLAN TO ATTEND August 10, 2021, 11AM EST – 4PM EST
Presentation by Dr. Williams: INTERNAL presentation on Science Side related to Mission #4: Synthetic Biology
Presentation by Aviva: INTERNAL subjects on Business Side: Issue #1 and #2
Presentations by INTERNS – Topics to be determined and announced
Issue #1:
The REDESIGN of LPBI’s Organizational Chart by Practices named Missions
We are including LPBI India
Each Practices named: Missions #1, #2, #3, #4
People assigned to each Mission will be on the Org Chart
Mission #1: NLP – Team in USA & India
Mission #2: Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph DBs
Advertisements
REPORT THIS AD
Mission #3: BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E
New Genre e-Book Architecture has the following Book architecture:
Bi-Lingual English to Spanish eTOCs
NLP Results with Audio interpretation of results by Domain knowledge Expert in several languages
English Editorial in Audio Podcast
STATE OF AFFAIRS for LPBI’s BioMed e-Series – 18 Books
Currently we have a massive effort of Converting ALL the electronic Table of Contents of the 18 books from English Text to Spanish Text. Same for the 18 Cover Pages
We may decide to
Convert the SPANISH TEXT to SPANISH AUDIO PODCAST
Domain Knowledge Expert INTERPRETATION of NLP RESULTS on six volumes:
Series B: Genomics – 2 volumes
Series C: Cancer – 2 volumes
Series A: Volume 1 – Nitric Oxide
Series E: Volume 4 – 3D BioPrinting
All above NLP interpretation of visualization products will be written by Domain knowledge experts as English Text:
Cancer & Genomics: Williams, LPBI USA
Cardiovascular: Vivek Lal, LPBI India
The Interpretations English Text will be subjected to:
Conversion of English Text to Sound: English Audio Podcast
Conversion of English Text to Spanish Text to Spanish Audio Podcast
Other Languages Audio Podcast: Japanese, Russian
Mission #4: Synthetic Biology: Drug discovery Galectins
LPBI NEEDS a lead MD or PhD for Mission #4 based in the USA and/or in India.
The intent is to:
LPBI USA and LPBI India will develop IP on targeting 12 Galectins as therapeutics using Synthetic Biology Software in Drug Discovery 💡
Testing the molecules by Dr. Nir in ABI Lab & SBH Sciences, Inc. wet labs
Give Dr. Nir Right of Use
Hosting the molecules in Blockchain Knowledge Graph Data Base
Open up the molecules for licensing in a cyber secured confidential Auction
Host molecules inventories from Technology Transfer Offices in several Academic centers around the Globe. We have relations to three Academic institutions in Israel, and three in the US
GLOBAL BUSINESS RELATIONS EXPLORED
Aviva’s Zoom meeting on 8/4
Person #X: regarding a Turnaround approach in the US
Aviva’s Zoom meeting on 8/11
Person #1: I am meeting on 8/11 with a person proposing him to contact on my behalf a leading Investment houses based in Israel – names of people to contact are provided by Aviva
Person #2: based in Israel for an Israel Investment Acquisition with a national good will
On 7/31/2021 Aviva approached directly:
Person #3: based in Israel head of a major investment house with sheer international investment horizon and book of deals for Referral to specific UK based Investment House, a Japanese IB and two UAE based IBs – all are on this book of business
Person #4: A Europe-based prospector for potential acquirers in Europe
TECHNOLOGY ISSUES EXPLORED
Issue #2:
Blink.com has AI technology for Key ideas finding in text for Mobile Devices
Apple Recommends The App All The Intellectuals Are Using To Beat Boredom – Blinkist Magazine
SHALL LPBI APPROACH BLINK.com
for application for their technology for MOBILE DEVICES to
LPBI’s BioMed 18 e-Books for used on MOBILE DEVICE?
@@@@@@@@@@
July 21, 2021 – LPBI USA BUSINESS SIDE – 11AM EST – 4PM EST
On July 21, 2021 at 11AM EST – We have LPBI July 2021 Board Meeting with all VENDORS to provide services to 2.0 LPBI
open to all addressees – All Summer and NLP Interns are encouraged to attend
July 21, 2021 – TECHNOLOGY SIDE with External Technology Vendors
Justifying the Launch of LPBI India todayis the Interaction between LPBI USAand LPBI India which is taking place multiple times every day
Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
Interactions among all members across Indiais mostly encouraged
We are preparing a MAP with all the locations in India of our VIRTUAL organization
We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
Interactions with Alumni of LPBI USAis mostly encouraged – we are very proud of each of you,
Congratulatory Remarks, each presenter from their own perspective:
LPBI USA Board member, Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
Aditya Bahl, MBA, LPBI USA, External Business Relationsto LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINTmeeting dedicated to Mission #2, below
Mission #1:
Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)
The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:
128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now
+6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Galleryof LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200
At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD
We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences
LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well
Mission #2:
Applications of Synthetic Biology Software to Galectins for design of new drug molecules.
Collaboration with Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
LPBI India will play a role in these tasks, please review:
Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom
Ten Minuteson on Clinical Trials for RAMATROBAN – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India
Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia
Sriram,Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021
Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST
Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articlesin multiple of LPBI e-Books, chiefly Cancer and Immunology
Rehearsal for the Presentation at 3:30PM EST with Linguamatics at the Insurer
On July 13, 2021 at 3:30PM EST – we have a major Presentation on Zoom with Linguamatics on NLP on LPBI’s Cancer & Oncology Content, Proof-of-Concept on Research Categories and Book Chapters
@@@@@@@@
AGENDA for 8-June, 2021
2.0 LPBI – Global Monthly Zoom Meetings in 2021
ALLIANCES SIDE – 11AM EST – 1PM EST
11AM EST – Presentation by Montero Language Services, Madrid, Spain – 15 minutes
Translation of each book Cover Page and each book electronic Table of Contents
Series A: Cardiovascular 6 volumes – Translated was completed – New Format was applied to Volumes 1 & 2, to be followed by Volumes 3,4,5,6
Series B: Genomics – was submitted for Translation
Series C, D, E – application of New Format is work-in-progress
Strategy for Promotion of Spanish Translation of LPBI’s BioMed e-Series of 18 Volumes in Medicine
Several channels for content promotion will be presented
12 – 1PM EST Aviva provides Briefing
The Spanish translation is an intent to increase and create MORE value for the LPBI 1.0 assets for sale
WE WISH TO EXERCISE AN OUTRIGHT SALE OF ASSETS IN THE CONTEXT OF A TURNAROUND – therefore WE requested QUOTES for NLP and for BLOCKCHAIN
Spanish translation enables RE-Publishing of each Book with a Bi-Lingual eTOCs and Cover Page
Spanish translation enables launch of a new Website for Spanish Speaking Scholarsaround the books
Spanish translation will generate Traffic and comments and book sales and Pages Downloads
Montero Language Services brought to the Table GTO for the PR and Buzz about the Spanish Translation
Montero Language Services might be seeking Government FUNDING for the Translation of ALL the Books in their entirety vs 2021 Translation of Cover Pages and eTOCs.
LPBI will give Montero Permission to publish all the books in their entirety in Spanish
BUSINESS SIDE – 1PM EST – 5PM EST
1PM EST Stefan Kienitz, CEO Patentmanager.de GmbH – Confirmed – 30 Minutes
Virtual Marking – for the first time with court-proof evidence – DLT Blockchained – with only one sticker identical for all products – without time-consuming ERP system assignment (patents/design/trademarks) – with fully automated legal statuses – pending/granted/lapsed – to secure your claims for damages – in USA+UK+AU Without marking – no damage compensation! Maybe the new feature – the DLT Blockchain Technology – can convince you? First information under: https://patentmanager.de/en/virtual-marking-ip-rights-watch
We consider 1 Summer INTERN that will work on Conversion of our articles in the Research Category “Interviews with Scientific Leaders” – a List of 283 articles into a Library of PODCASTS
3:30PM EXT – Dr. John McCarthy – An Insider’s View to Pharma and HC Insurance Payers – 40 minutes
4:10PM EST – Aviva’s Summary – 20 minutes
LPBI strategy is for BLOCKCHAIN technology to be MARRIED to NLP FOR CONTENT MONETIZATION
LPBI is Seeking collaboration with Pharma and/or clinical decision support/healthcare research for building a Use Case for NLP on LPBI’s Contents able to serve both Pharma and CROs and Payers
We are trying the Healthcare Insurer for that purpose – demonstrate value to a PAYER
WE requested QUOTES for NLP and Blockchain TO CREATE THE POTENTIAL FUTURE FOR 2.0 LPBI
WHY BUY 1.0 LPBI nine IP Assets?
BECAUSE YOU CAN DO NLP AND Monetize content on BLOCKCHAIN transactions network
To sell the IP ASSETS you need to create the Future Vision about WHAT CAN BE DONE WITH WHAT YOU BUY
That vision is created by running NLP and create the blueprint design for a Digital Store inside a HEALTHCARE Digital Marketplace which is connected to a Blockchain Transactions Network for SELLING CONTENT B2B and B2C
@@@@
AGENDA for 11-May, 2021
2.0 LPBI – Global Monthly Zoom Meetings in 2021
SCIENCE SIDE – 11AM EST – 1PM EST
Internal Discussion by Medical Text Analysis with NLP Team – Dr. Williams explains PPT by Linguamatics
External Science Presentation – TBA
BUSINESS SIDE – 1PM EST – 5PM EST
Presentations to LPBI BOARD on May 11, 2021
By
3rd Parties, Guest Presenters
Olivier Jarry, Atlas Advisors, NY, NY
Dr. McCarthy, Confidential Healthcare Insurer, Canton, MA
Fritz Handtke, Montero, Madrid, Spain
Olivier Jarry– your presentation on May 11, 2021 1PM EST (60 minutes) – should be a TAILORED presentation of your approach for the situation presented in this document
Internal Discussionon Olivier’s Presentation May 11, 2021 2PM EST (20 minutes)
McCarthy – your presentation on May 11, 2021 2:20PM EST (20 minutes) – AI in Healthcare: Context for NLP
Fritz Handtke– your presentation on May 11, 2021 2:40PM EST (20 minutes) – Brief statement of the state of affairs on
the Spanish Translation, and on
the Joint Marketing Campaign
Attn: LPBI External Relations:
Mr. Bahl, Mr. Gamota, Mr. Halpern
May 11, 2021 3PM EST – Please eachpresent 20 minutes,
Your own approach to the situation presented in this document
What is your approach for Part 3 in the attachment?? See it here UPDATED on 4/25/2021
Forthcoming meetings with Linguamatics/IQVIA – Meeting #2 and #3
PPT #1: Description of 1.0 LPBI and 2.0 LPBI as in this document – needed for the Presentation to HC Insurer
PPT #2: How a Joint Marketing Campaign AND a business partnership [IQVIA, HC Insurer] can be used for TofO
PPT #3: Creative approaches to prospecting for TofO – needed in interactions with M&A agencies
Attn: Dr. Ofer
By May 5, 2021 – >> Please create AT LEAST ten IDEASthat Joel needs to incorporate into the three PPTs
Attn: Dr. Williams, Dr. Pearlman – 30 minutes
On May 11, 2021 4:30PM EST – 15 minutes each PPT
I wish and need to receive from each of you
Comments by Dr. Pearlman on the core technologies: NLP and Blockchain
Comments by Dr. Williams on HOW to improve the document and Submit an Improved version with Tracking changes in color
SUMMARY – AVIVA – 10 minutes
THANK YOU
See you all on
May 11, 2021 at 1PM Business Side
May 11, 2021 at 11AM Science Side
@@@@@@@@
AGENDA for 6-April, 2021
2.0 LPBI – Global Monthly Zoom Meetings in 2021
SCIENCE SIDE – 11AM EST – 1PM EST
Tetz & Dr. Kogan– Summary of Discovery and Discussion – Drug-Device Antibiotic resistance – 60 minutes
Gupta – The Genesis and Chemoprophylaxis of AstraZeneca Vaccine induced Thrombotic Events?
Comments by Williams
BUSINESS SIDE – 1PM EST – 4PM EST
1PM – 1:45PM Presentation: Dan Halpern
Advertisements
REPORT THIS AD
Relevant experience to LPBI’s SPACE & Perspective on Strategic Positioning of LPBI
1:45PM – 2:15PM Q&A
2:15PM – 3:15PM JOEL on PPT & Own Views on Strategic Positioning of LPBI
3:15PM – 4PM EST Aviva on Milestones of 2.0 LPBI 1Q 2021 and Plans for 2Q 2021
MEDICAL TEXT ANALYSIS WITH NLP TEAM
REMINDER: APRIL 15, 2021 10AM EST
PPT PRESENTATION WITH LINGUAMATICS
@@@@@@
AGENDA for 9 MARCH, 2021
2.0 LPBI – Global Monthly Zoom Meetings in 2021
SCIENCE SIDE – 11AM EST – 1PM EST
9-Mar-21
Dr. Tetz 30 minutes – Drug-Device Antibiotic resistance
Dr. Kogan 30 minutes – Drug-Device Antibiotic resistance
Dr. Ajay Gupta & Prof. Saul Yedgar – 30 minutes discussion [No PPT presentations]
Ajay Gupta, MD – UC, Irvine, CA
Clinical Professor, Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine, Chief Scientific Officer, Rockwell Medical Inc., www.rockwellmed.com President & CSO, Applied Medical Technologies LLC
Ramatroban, a thromboxane A2 receptor antagonist for thrombo-inflammation in COVID-19’
Saul Yedgar – Hebrew University Medical School, Jerusalem, Israel
Inclusive vs. Selective Control Of Inflammatory Lipid Mediators for Treating Inflammatory Conditions
BUSINESS SIDE – 1PM EST – 4PM EST
1PM – 1:30PM Presentation
1:30PM -1:45PM Q&A
DS, CMAA, Medworld Advisors, Andover, MA
Global M&A; Outsourced Biz Development Leader (B,D&L) for Medical SME and Emerging Tech Companies
1:45PM – 2:15PM Presentation
2:15PM – 2:30PM Q&A
I_del_C, Madrid, Spain
Global Operations Director, Montero LS
2:30PM – 3:00PM Presentation
3:00PM – 3:15PM Q&A
MvR, MD, Helsinki, Finland
Senior Business Advisor Invest, Capital Helsinki area (Health; Med-Tech, Pharma). SPECIALIST IN INTERNATIONAL BUSINESS
3:15PM – 4:00PM LPBI – Goal attainment in last 4 weeks
Aviva
Joel
@@@@@@@@@
AGENDA for 9-February-2021
2.0 LPBI – Global Monthly Zoom Meetings in 2021
SCIENCE SIDE – 11AM EST – 1PM EST
Ajay Gupta, MD – 30 minutes
Clinical Professor, Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine, Chief Scientific Officer, Rockwell Medical Inc., www.rockwellmed.com President & CSO, Applied Medical Technologies LLC
‘Ramatroban, a thromboxane A2 receptor antagonist for thrombo-inflammation in COVID-19’
Prof. Fitzgerald proposes that thromoboxane A2 and PGD2 receptor antagonists can serve as antithrombotic and immunomodulatory agents in COVID-19 respectively.
Ramatroban is the only dual Thromboxane A2 / TP and PGD2/DPr2 receptor antagonist. Ramatroban has an excellent safety profile having been used for allergic rhinitis in Japan for past 20 years.
Ramatroban is ideally suited for treatment of COVID-19 at all stages of the disease and all severities. FDA has allowed us to proceed with clinical trials but Bayer has declined to provide the drug.
It is tragic because children, even those with mild symptoms, exhibit microvascular thrombosis and thrombotic microangiopathy (Diorio et al, 2020). Many children have recovered from acute illness but suffering from long COVID.
Yigal Blum – ex-VP, SRI International – 15 minutes
Clinical Trial with New Drug for COVID-19: amorphous structure and nanometric size CaCO3
crystalline and large particles of CaCO3 has no effect on our activities, as it has the usual efficacy of the calcium substance mostly used in the food supplement market. Our ACC is unique because of its amorphous structure and nanometric size.
BUSINESS SIDE – 1PM EST – 4PM EST
1PM EST – 1:30PM EST – Professor James Jordan, CMU
CEO of StraTactic, Inc. | Strategic Healthcare Consultant | Healthcare Professor, Carnegie Mellon | Former Fortune 20 Executive
(b) the results of PRIORITY #1, above: Medical Text Analysis using NLP, ML-AI
PRIORITY #3
DESIGN of CONTENT PROMOTION campaigns
12:45PM EST – 1:00PM EST
Conxa Catot, Contentednet.com, Barcelona, Spain
Introductions of LPBI in the Publishing and Pharmaceutical Sectors in Spain
Explorations for Translation from English to Spanish the electronic Table of Contents (eTOCs) for 1.0 LPBI’s BioMed e-Series: 17 e-Books in Medicine
1PM EST – 2:00PM EST
Martin R. Schiller, PhD
Chairman, CEO, and Founder, Heligenics Inc.
Executive Director, NV Institute of Personalized Medicine (UNLV)
Prabhu Endowed Professor
Principal Investigator, Schiller Laboratory of Applied Bioinformatics
Principal Investigator, Personalized Medicine In NV COBRE
Gene Mutation Functional Libraries (GMLs) meet four needs at many stages of the drug development pipeline in the pharmaceutical industry:
Preclinical drug evaluation. You can better select compound to advance to human testing by understanding how common human genetic variation will influence resistance, poor efficacy, and cytotoxicity prior to an expensive clinical trial.
Superprecision clinical trials. The GMLs are a panel of genetic markers in the drug target gene for segregating participants into different arms in a clinical trials. An arm excluding participants with genetic variants that are susceptible to resistance, poor efficacy or cytotoxicity enables a better clinical trial design. Our product uses all genetic variants in a target gene, whereas it is common practice to use a single genetic marker for a targeted therapy.
Rescuing drugs that failed in a clinical trial. Similar to drug development, you can take a therapy that previously failed in a clinical trial by redesigning a new clinical trial as above. Thereby a failed conventional therapy can be converted into a successful targeted therapy.
Identify Off-target receptors.The FDA requires investigation of off-target drug effects. We experimentally measure drug stimulation of cell signaling pathways for each human receptor with our GigaAssay platform. Identifying off-target receptors can help to select better lead and derivative compounds to limit adverse effects in a future trial or to identify new receptors for repurposing drugs for new indications.
BUSINESS SIDE – 2PM EST – 4PM EST
2PM EST – 3PM EST – Amber Harley
Proposal of IT Architecture for 2.0 LPBI Strategies for Content Monetization IT Transaction infrastructure with Blockchain Ledger features and Permissions & Recommendation engine
Existing 1.0 LPBI IP of four Corpuses
(a) Journal Articles (+6,000)
(b) 17 Books in Medicine
(c) 100 Volumes of e-Proceedings & Tweet Collections
(d) Gallery of Biological Images (+5000)
Starting 2021 – To be created 2.0 LPBI IP using (a), (b), (c), (d)
2.1 Medical Text Analysis with NLP, ML-AI: DBs for WordClouds and Hyper-graphs
1.1 Starting with All 17 Books: Step 1: 2 volumes in Genomics and 2 in Cancer
1.2 Adding Audio capability to All Articles in 17 Books
1.3 Foreign Languages Translation of ALL 17 eTOCs and of the Domain Knowledge Experts Interpretation to Hyper-graphs
3:00PM EST – 4:00PM EST – 2.0 LPBI Internal Affairs
Williams – Proof of Concept – Planning Meeting with Insurer
Bari Weiss @ FreePress@bariweissTHREAD: THE TWITTER FILES PART TWO. TWITTER’S SECRET BLACKLISTS.
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
#ChatGPT #openai @MIT
Another case,
Aviva Lev-Ari, PhD, RN
for the #curation #methodology
+2.2MM Views, +140,000 page downloads
@pharma_BI @AVIVA1950
#scienceandtechnology #pharma
Go to
https://lnkd.in/eteNqpF
Click on
Founder
@Berkeley